System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Maarten de Wit is an expert in Rheumatology at OMERACT Patient Research Partner Network (Netherlands). As of October 2026, ScienceLeadR ranks Maarten de Wit in the top 1% of experts worldwide for Arthritis and Skin Diseases, Papulosquamous. Maarten de Wit has authored 347 publications, the most recent in 2026, and is an investigator in 6 clinical trials, 1 of them ongoing. SLR score: 1,063 (community average: 125). How the SLR is computed.

LeadR Profile

Maarten de Wit OMERACT Patient Research Partner Network Netherlands
1 063 ScienceLeadR Reputation 1063

Unlock

Register Login
Network Map

Rheumatology

Subspecialties: Dermatology - Internal Medicine - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2007 - 2026
Source: PubMed

OMERACT Patient Research Partner Network

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 347

Citations

Citations: 25 739 1st author: 36 Last author: 22 Unique author: 5

Main journals

Ann Rheum Dis 106
J Rheumatol 48
Rheumatology (Oxford) 16
RMD Open 15
Arthritis Care Res (Hoboken) 12

Best Journals

Nat Rev Rheumatol 2
Science 2
Lancet 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Defining and interpreting the clinical relevance of intervention effects for patient-reported outcomes: the smallest worthwhile effect construct.
PMID 42493235 — patient reported outcome measures, research		BMJ Evid Based Med20262
Understanding patient and physician global assessments in rheumatoid arthritis: A meta-epidemiological study of core outcome set performance.
PMID 42330661 — arthritis, epidemiologic studies, rheumatic diseases, physicians, arthritis, rheumatoid, therapeutics		Semin Arthritis Rheum20260
Prologue: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2025 Annual Meeting.
PMID 42414046 — arthritis, psoriatic, arthritis, rheumatic diseases, research, psoriasis		J Rheumatol20260
Bimekizumab Improves Health Status and Work Productivity, With Reduced Productivity Costs, to 3 Years in Axial Spondyloarthritis and Psoriatic Arthritis.
PMID 42386286 — arthritis, psoriatic, cost savings, arthritis, health status, rheumatic diseases, work, axial spondyloarthritis		J Rheumatol20260
Composite outcome measures that successfully differentiate active treatments from placebo in psoriatic arthritis trials: a GRAPPA-OMERACT systematic review and network meta-analysis.
PMID 42248769 — arthritis, psoriatic, arthritis, rheumatic diseases, network meta-analysis, therapeutics		Ann Rheum Dis20260

Clinical Studies 6

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 5
Phase 4 1

By status:

Completed 4
Recruiting 2

By type:

Interventional 3
Observational 3

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 1
multicentric5to9 0
multicentricup10 2

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
HIPPOCRATES Prospective Observational Study
NCT05858528 — arthritis, psoriatic, blood, arthritis, risk factors, psoriasis, prognosis		N/ARecruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS